ClinicalTrials.gg
Active, not recruitingNCT02960022Updated Oct 13, 2026

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

A Phase 2 interventional study of enzalutamide and abiraterone acetate in Prostate Cancer, sponsored by Astellas Pharma Global Development, Inc.. Active, not recruiting at 233 sites in 38 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment

Updated Oct 13, 20261 site removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
900
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.

Planned enrollment
10th of 125
900 · median 52
Started
2016
with 8 others
Phase 2
65 of 125
8 open now
Primary completion
2029-07
later than 35 of 37 live
Registered
71st of 125
by date
Lead sponsor
6 of 125
Astellas Pharma Global Development, Inc.

Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 10th largest by planned enrollment, is one of 9 that started in 2016, is one of 65 in phase 2, reaches primary completion later than 35 of the 37 other live ones, and was the 71st registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 17 open studies →

About enzalutamide

enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies testing enzalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutamide clinical study sponsored by Astellas or Medivation (i.e., parent study) which has completed, at a minimum, the primary analysis or the study specified evaluation period.

Read the detailed description

Subjects must continue on the treatment regimen that the subject was receiving in the prior study. Dose changes of any of the prior therapies subjects were receiving on the previous protocol are allowed after medical monitor approval. The day 1 visit for this study should coincide with the last treatment visit for the study the subject will be enrolling from (≤ 7 days post last visit of parent study) unless the subject is on treatment suspension. The subjects will be followed according to the local institution's standard of care and will be required to return to the institution every 24 weeks (± 7 days) to review adverse events (AEs), collect concomitant medications and confirm that no discontinuation criteria are met. At each visit and at every 12 weeks (IP only visit) subjects are to return all dispensed study drug and to receive more study drug if applicable. All AEs (new and ongoing from the study the subject is enrolling from) and Serious Adverse Events (SAEs) (including death), will be collected from the time the subject signs the consent form until the end of study visit.

After the marketing approval in South Korea, this study continued as "post marketing clinical study" in South Korea. In the rest of the countries which participated in this study, this study continued as clinical study.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • prednisone
  • MDV3100
  • enzalutamide
  • Xtandi
  • abiraterone acetate
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must currently be receiving enzalutamide or assigned to receive enzalutamide (if on treatment suspension) for prostate cancer in a study sponsored by Astellas or Medivation and, based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible.
  • Subject is able to continue on the treatment regimen that they were receiving or were assigned to receive in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dose change in Androgen deprivation therapy (ADT) or dropping of a combination therapy) approval from a medical monitor is required prior to enrollment.
  • Subject is able to swallow enzalutamide capsules and comply with study requirements.
  • Subject and female partner who is of must continue to use 2 forms of , of which 1 must be highly effective and 1 must be a barrier method throughout the study and for 3 months after final enzalutamide administration.
  • Subject agrees to avoid sperm donation during the study and for at least 3 months after final enzalutamide administration.
  • Subject agrees not to participate in another interventional study while on treatment.

Canada Specific:

  • Institutional Review Board (IRB)/Independent Ethics Committee (IEC) approved written and privacy language as per national regulations (e.g., Health Insurance Portability and Accountability Act authorization for the United States sites) must be obtained from the subject prior to any study-related procedures.
  • Subject must currently be receiving enzalutamide for breast cancer in a study sponsored by Astellas or Medivation/Pfizer and based on the investigator's assessment, benefit from continued treatment. Subjects participating in investigator-initiated trials are not eligible.
  • Subject is able to continue on the treatment regimen that they were receiving in the prior study. If in the investigator's assessment, a change is needed to the subject's regimen (e.g., dropping of a combination therapy) approval from a medical monitor is required prior to enrollment.
  • Subject is able to swallow enzalutamide capsules and comply with study requirements.
  • Subject is either:
  • Of nonchildbearing potential:
  • (defined as no spontaneous menses for at least 12 months prior to Day 1 with follicle stimulating hormone (FSH) > 40 IU/L at Day 1 for women \< 55 years of age),
  • documented surgically sterile or status post hysterectomy (at least 1 month prior to Day 1),
  • Or, if of childbearing potential,
  • must have a negative urine pregnancy test at Day 1 before the first dose of study drug is administered,
  • must use 2 acceptable methods of birth control starting at Day 1 and through 6 months after the final study drug administration,
  • must not donate ova starting at first administration of study intervention and throughout 6 months after final study intervention administration.

The 2 acceptable methods of birth control are as follows or per local guidelines where these require additional description of contraceptive methods:

  • A barrier method (e.g., condom by a male partner) is required; AND
  • One of the following is required:
  • Placement of an intrauterine device (IUD) or intrauterine system (IUS);
  • Additional barrier method including occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository;
  • Vasectomy or other surgical castration at least 6 months before Day 1.
  • The subject must not be breastfeeding at Day 1 or during the study period, and for 6 months after the final study drug administration.
  • Subject agrees not to participate in another interventional study while on treatment.

Exclusion criteria

Exclusion Criteria:

  • Subject met any of the discontinuation criteria or whose cancer progressed on the current enzalutamide clinical study in which subject is enrolling from.
  • Subject requires treatment with or plans to use either of the following:

    • New systemic therapy for subjects cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment.
    • therapy other than enzalutamide.
  • Subject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide.
  • Subject has any concurrent disease, infection, or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data.

Canada Specific:

Subject will be excluded from participation if any of the following apply:

  • Subject met any of the discontinuation criteria or whose cancer progressed on the current enzalutamide clinical study in which they are enrolling from.
  • Subject requires treatment with or plans to use any of the following:
  • New systemic therapy for their cancer (palliative radiation therapy is allowed). The treatment with agents administered during previous studies which was stopped and then restarted during this study does not represent new treatment.
  • Investigational therapy other than enzalutamide.
  • Subject is currently participating in an investigator-initiated interventional trial and receiving enzalutamide.
  • Subject has any concurrent disease, infection, or comorbid condition that interferes with the ability of the subject to participate in the study, which places the subject at undue risk or complicates the interpretation of data in the opinion of the investigator.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
900 participants (estimated)

Study arms

  • Experimental
    enzalutamide

    Subjects will receive enzalutamide orally once daily at the same time each day

    Drug: enzalutamide

  • Experimental
    enzalutamide plus abiraterone acetate and prednisone

    Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide once daily

    Drug: enzalutamide · Drug: abiraterone acetate · Drug: prednisone

  • Experimental
    Enzalutamide plus leuprolide acetate

    Subjects enrolling from study MDV3100-13 (EMBARK) study may receive leuprolide acetate once every 12 weeks in addition to enzalutamide once daily

    Drug: enzalutamide · Drug: Leuprolide acetate

Interventions

  • Subjects will receive enzalutamide orally once daily at the same time each day.

    Also known as: MDV3100, Xtandi

  • Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide

  • Subjects enrolling from study 9785-CL-0011 or MDV3100-10 (PLATO) study may receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide

  • Subjects enrolling from study MDV3100-13 (EMBARK) study may receive leuprolide acetate once every 12 weeks in addition to enzalutamide once daily

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events

    Time frame: Until End of Study (Up to 96 Months)

07

Study locations

233 sites
  • Site US10052
    Anchorage, Alaska 99503, United States
  • Site US10011
    Tucson, Arizona 85741, United States
  • Site US10040
    Los Angeles, California 90024, United States
  • Site US10009
    Los Angeles, California 90048, United States
  • Site US10008
    San Bernardino, California 92404, United States
  • Site US10042
    San Diego, California 92108, United States
  • Site US10028
    Stanford, California 94305, United States
  • Site US10001
    Aurora, Colorado 80045, United States
  • Site US10017
    Denver, Colorado 80211, United States
  • Site US10050
    Washington D.C., District of Columbia 20037, United States
  • Site US10049
    Daytona Beach, Florida 32114, United States
  • Site US10002
    Chicago, Illinois 60637, United States
  • Springfield Clinic, LLP
    Springfield, Illinois 62701, United States
  • Site US10007
    Jeffersonville, Indiana 47130, United States
  • University of Kansas Medical Center
    Kansas City, Kansas 66160, United States
  • Site US10066
    Lenexa, Kansas 66214-1656, United States
  • Site US10029
    Towson, Maryland 21204, United States
  • Site US10032
    St Louis, Missouri 63110, United States
  • Nebraska Medical Hospital
    Omaha, Nebraska 68114, United States
  • Site US10023
    Omaha, Nebraska 68130, United States
  • Site US10004
    Hackensack, New Jersey 07601, United States
  • Site US10024
    Garden City, New York 11530, United States
  • Site US10055
    New York, New York 10065, United States
  • Site US10059
    New York, New York 10065, United States
  • Hudson Valley Urology, PC
    Poughkeepsie, New York 12601, United States
  • Site US10053
    Syracuse, New York 13210, United States
  • Site US10030
    Chapel Hill, North Carolina 27599, United States
  • Site US10062
    Charlotte, North Carolina 28207, United States
  • Site US10031
    Greensboro, North Carolina 27403, United States
  • Eastern Urological Associates
    Greenville, North Carolina 27834, United States
  • Site US10046
    Winston-Salem, North Carolina 27157, United States
  • Site US10035
    Cincinnati, Ohio 45212, United States
  • Site US10022
    Springfield, Oregon 97477, United States
  • Site US10027
    Lancaster, Pennsylvania 17604, United States
  • Site US10005
    Pittsburgh, Pennsylvania 15232, United States
  • Site US10018
    Charleston, South Carolina 29414, United States
  • Carolina Urologic Research Center
    Myrtle Beach, South Carolina 29572, United States
  • Site US10041
    Nashville, Tennessee 37232-2765, United States
  • Site US10010
    Dallas, Texas 75231, United States
  • Site US10034
    Houston, Texas 77024, United States
  • Site US10043
    Houston, Texas 77030, United States
  • Site US10014
    Norfolk, Virginia 23502, United States
  • Site US10015
    Virginia Beach, Virginia 23462, United States
  • Virginia Mason Medical Center
    Seattle, Washington 98101, United States
  • Site US10038
    Seattle, Washington 98109, United States
  • Site US10021
    Madison, Wisconsin 53792, United States
  • Site AR54005
    Buenos Aires, Buenos Aires F.D. C1120AAT, Argentina
  • Site AR54007
    Rosario, Santa Fe Province S2000DSV, Argentina
  • Site AR54008
    Buenos Aires, Argentina
  • Site AR54003
    Cordorba, Argentina
  • Site AR54006
    San Miguel de Tucumán, T4000IAK, Argentina
  • Site AR54002
    San Miguel de Tucumán, Argentina
  • Site AU61014
    Albury, New South Wales 2640, Australia
  • Site AU61001
    Tweed Heads, New South Wales 2485, Australia
  • Site AU61012
    Wahroonga, New South Wales 2076, Australia
  • Site AU61017
    Wahroonga, New South Wales 2076, Australia
  • Site AU61006
    Ashford, Australia
  • Site AU61019
    Ballarat, 3350, Australia
  • Site AU61007
    East Bentleigh, 3165, Australia
  • Site AU61009
    Malvern, Australia
  • Site AU61021
    Parkville, Australia
  • Site AU61008
    South Brisbane, Australia
  • Site AU61016
    St Albans, 3021, Australia
  • Site AU61004
    Westmead, 2145, Australia
  • Site AT43001
    Vienna, 1090, Austria
  • Site BE32002
    Kortrijk, West-Vlaanderen 8500, Belgium
  • Site BE32009
    Anderlecht, 1070, Belgium
  • Site BE32004
    Brussels, B-1090, Belgium
  • Site BE32011
    Ghent, 9000, Belgium
  • Site BE32007
    Hasselt, Belgium
  • Site BE32008
    Leuven, 3000, Belgium
  • Site BE32001
    Liège, 4000, Belgium
  • Site BE32003
    Turnhout, 2300, Belgium
  • Site BR55007
    Porto Alegre, Rio Grande do Sul 90430-090, Brazil
  • Site BR55009
    Bahia, 41253-190, Brazil
  • Site BR55008
    Campinas, Brazil
  • Site BR55011
    Jaú, Brazil
  • Site BR55002
    Rio Grande, 90610-000, Brazil
  • Site BR55010
    Santo André, 09060-650, Brazil
  • Site CA15003
    Kingston, Ontario K7L 3J7, Canada
  • Site CA15021
    Toronto, Ontario M4N 3M5, Canada
  • Site CA15001
    Granby, Quebec J2G 8Z9, Canada
  • Site CA15019
    Abbotsford British Columbia, V2S 3N5, Canada
  • Site CA15020
    Greenville, L6R 3J7 27834, Canada
  • Site CA15011
    Montreal, Canada
  • Site CA15017
    Oakville, L6H 3P1, Canada
  • Site CA15022
    Québec, QC / G1S 4L8, Canada
  • Site CL56007
    Santiago, RM 7500787, Chile
  • Site CL56005
    Santiago, RM 75009, Chile
  • Site CL56006
    Viña del Mar, Valparaiso 2520598, Chile
  • Site CL56004
    IX Region, Chile
  • Site CL56002
    Santiago, Chile
  • Site CL56001
    Viña del Mar, Chile
  • Site CN86003
    Hubei, 430030, China
  • Site CN86010
    Hunan, 410013, China
  • Site CN86005
    Nanjing, China
  • Site CZ42004
    Olomouc, 775 20, Czechia
  • Site CZ42002
    Olomouc, 779 00, Czechia
  • Site CZ42001
    Prague, 16000, Czechia
  • Site CZ42003
    Prague, Czechia

Showing the first 100 of 233 sites across 38 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.

Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.

Data sharing details ↗ · www.clinicaltrials.astellas.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2016 (actual). Primary completion is estimated for Jul 2029, 151 months after the start.

Of 114 industry-sponsored phase 2 interventional studies under Prostatic Neoplasms, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 45. This study's planned 151 months is above that.

Counting every sponsor, half of 724 studies reached it within 53 months; a quarter within 34 and three quarters within 81.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2016
First posted
Nov 9, 2016
StartActual
Dec 22, 2016
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site removed
Show 1 removed
  • Site BE32005 · Ghent, Belgium
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    1 site removed
    Show 1 removed
    • Site BE32005 · Ghent, Belgium
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02960022
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Nov 9, 2016
Start date
Dec 22, 2016
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Associate Medical Director
study director · Astellas Pharma Global Development, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enzalutamide

Start the discussion